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OVERVIEW — This brief provides a description of prescription drug use in
nursing homes and a summary of current policy issues in this area. The brief
first profiles the nursing home pharmaceutical market, outlining the major
trends in demographics and drug utilization, the supply chain by which drugs
go from manufacturers to pharmacies to nursing home residents, and the al-
ternative arrangements by which prescription drugs in nursing homes are
financed. The brief then provides a synopsis of current policy issues, focusing
in turn on cost containment and quality improvement initiatives.
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Prescription Drug Use in Nursing
Homes: Managing Costs and
Quality in a Complex Environment
The rise in spending on prescription drugs has emerged as a central
policy issue for the Medicare and Medicaid programs. At the federal
level, debate about prescription drugs has focused primarily on the ad-
dition of an outpatient prescription drug benefit to the Medicare pro-
gram. At the state level, concern has been driven by double-digit in-
creases in Medicaid drug spending. Despite the prominence of the pre-
scription drug cost issue, however, relatively little attention has been
paid thus far to the unique and important topic of pharmaceuticals pre-
scribed to nursing home residents.
Federal consideration of nursing home pharmacy issues in the past has
mainly been limited to quality and safety concerns, specifically the pre-
vention of inappropriate sedation. For a variety of reasons, however, the
management of prescription drugs in nursing homes is now poised to
emerge as a critical policy issue. First, state awareness of drug spending
in nursing homes has grown as budget problems have forced increas-
ingly aggressive state Medicaid cost containment. Second, as pharma-
ceutical innovation continues, new and expensive medications are rap-
idly being developed for the elderly population. Third, clinicians are con-
cerned about the increasing utilization of pharmaceuticals by nursing
home residents and the high incidence of drug-related adverse events.
DRUG THERAPY IN NURSING HOMES:
MAJOR TRENDS
The United States faces a growing elderly population and an increasing
level of frailty among its citizens living in long-term care facilities. The
aging of the baby boom generation is predicted to propel a rise in the
percentage of the population over age 75 from 5.8 percent in 1997 to 9.4
percent in 2025.1 At the same time, advances in medical technology will
allow sicker individuals to live longer, sometimes with inadequate hous-
ing, insufficient social supports, and/or significant nursing care require-
ments. While alternatives to nursing homes (such as home health and
assisted living facilities) are likely to proliferate and become more impor-
tant, a demand for nursing home care, if even only among the most frail,
will likely grow concurrently with the growth of the elderly population.
Data from the National Nursing Home Survey indicate that, in 1997,
there were an estimated 1.6 million nursing home residents living in
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approximately 17,000 nursing homes nationwide.2 Of these residents,
90.3 percent were over age 65, and 46.5 percent were over age 85.3 Data
from the Agency for Healthcare Research and Quality (AHRQ) indicate
that females comprise 71.6 percent of all nursing home residents and
that 83 percent of residents receive help with three or more activities of
daily living, or ADLs, including bathing, dressing, toileting, transfer-
ring from a bed or chair, feeding, and mobility.4
A 2000 study of nursing facilities revealed that individual nursing home
residents receive an average of 6.7 routine prescription medications per
day and 2.7 additional medications on an “as needed” basis.5 The most
commonly prescribed medications, according to an independent survey,
are gastrointestinal agents (including laxatives, enemas, and acid secre-
tion reducers), analgesics (including acetaminophen and aspirin), cardio-
vascular medications (including Digoxin, diuretics, and nitrates), vita-
mins and supplements (including multivitamins and potassium), and
psychoactive medications (including sedatives and hypnotics,
antipsychotics, and antidepressants).6 This list accords with preliminary
findings from the Office of the Assistant Secretary for Planning and Evalu-
ation in the U.S. Department of Health and Human Services (DHHS),
which is currently studying the use of pharmaceuticals among Medicare
beneficiaries in nursing homes.7 (Medicare recipients tend to have shorter
lengths of stay than the average nursing home resident.)
The number of drugs prescribed to nursing home residents has been in-
creasing. A recent survey of pharmacists showed that routine medication
orders in nursing homes increased by 14 percent from 1997 to 2000.8 The
percentage of nursing home residents using nine or more prescription
medications per day also rose from 18 percent in 1997 to 27 percent in
2000.9 These trends have produced mixed reactions within the medical
and policy communities: on the one hand, clinicians acknowledge the
possible increase in quality resulting from increased use of appropriate
medications; on the other, experts worry about the potential for inappro-
priate medication use, adverse drug reactions and interactions, and in-
creasing drug costs.
The recent growth in nursing home drug utilization is due to a number of
factors, including technologic innovation in pharmaceuticals. The last 15
years have seen the development of safer alternatives to traditional medi-
cations (for example, newer antipsychotic drugs with better side-effect
profiles than traditional agents), as well as new categories of medications
that fill important needs (for example, selective serotonin reuptake in-
hibitors for depression and statin drugs for reducing serum cholesterol).
Pharmaceutical innovation and the rapid diffusion of more expensive
therapeutics are likely to continue—a 2001 survey conducted by the Phar-
maceutical Research and Manufacturers of America indicated that there
are 261 drugs in development to treat diseases of aging (for example,
Alzheimer’s disease, osteoporosis, and arthritis), as well as 122 medi-
cines for heart disease and stroke and 402 medicines for cancer.10
Routine medication or-
ders in nursing homes
increased by 14 percent
from 1997 to 2000.
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SUPPLY OF PHARMACEUTICALS
TO NURSING FACILITIES
Nursing homes typically acquire drugs for administration to residents by
means of a standard supply chain, illustrated in Figure 1. The pivotal role
in this supply chain is played by pharmacies, which are involved not only
in drug supply and distribution, but also in activities ranging from price
negotiations to quality improvement efforts. Currently, over 80 percent
of the nursing home beds in the United States are served by “institu-
tional” pharmacies that cater specifically to nursing homes and other fa-
cilities.11 However, some nursing homes are served by independent com-
munity pharmacies or retail pharmacy chains; the nursing home market
share claimed by institutional pharmacies varies from state to state.
Regardless of the type of pharmacy, federal and state laws require phar-
macies that serve nursing homes to maintain extended drug control and
distribution systems that exceed the standards for pharmacies dispens-
ing only to outpatients. As pharmacies that specialize in long-term care,
institutional pharmacies tend to offer additional services to support the
special needs of nursing homes, including 24-hour-a-day drug delivery,
maintenance of medication profiles and drug inventory systems, repack-
aging of drugs from bulk supplies into unit doses for controlled admin-
istration, and maintenance of emergency kits.
Five national chains provide the bulk of institutional pharmacy services
to nursing homes in the United States (Table 1). Two of the nation’s five
national institutional pharmacy chains (NeighborCare and Kindred Phar-
macy Services) are owned by larger companies (Genesis Health Ventures
FIGURE 1
Typical Supply of Pharmaceuticals to Nursing Facilities
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and Kindred Healthcare, respectively) that also run
nursing homes, and one (PharMerica) is a subsid-
iary of a wholesale distributor (Amerisource
Bergen). The last few months have seen significant
merger and acquisition activity within the indus-
try. In July 2002, Genesis and NCS HealthCare an-
nounced that Genesis would acquire NCS and fold
its operations into its NeighborCare division; in
response, Omnicare launched a hostile tender of-
fer for NCS shares. As this issue brief was being
prepared, NCS had filed suit against Omnicare and
was preparing shareholder proxies for the proposed
NeighborCare merger.12
Federal law requires all nursing homes to contract
with a consultant pharmacist, who is responsible
for ensuring that resident drug use is safe and ef-
fective and that facilities are in compliance with
federal and state regulatory requirements. Contrac-
tual arrangements vary widely—consultant pharmacists may be inde-
pendent or may be employees of either the nursing home or a phar-
macy. Most institutional pharmacies offer consultant pharmacy services
as part of their standard negotiations with client nursing homes. New
Jersey is the only state with a conflict-of-interest provision stipulating
that consultant pharmacists may not be employed by long-term care
pharmacies.13
In most states, both pharmacies and nursing homes are allowed to main-
tain formularies, that is, lists of drugs that are either recommended or
accepted for payment. If the pharmacy or nursing home is large enough,
it may extract rebates from manufacturers in exchange for listing their
product(s) on the formulary. Industry representatives state that thera-
peutic value is the most important factor in the decision to include a
drug on a formulary but that cost is also considered when comparing
two drugs of equal therapeutic value.14 Typically, neither pharmacies
nor nursing facilities are required by law to pass their rebates on to the
end payer.
FINANCING
Three different sources are available for financing nursing home care:
Medicaid, Medicare, and private sources (including both personal funds
and long-term care insurance). Medicare pays for nursing home care only
for limited time periods after an acute hospitalization. For chronic long-
term care, most individuals enter nursing homes as private-pay residents,
using a combination of resources (such as Social Security or pension
income and personal assets) to pay their expenses. Many residents even-
tually “spend down” their resources and meet the requirements for
2001 Revenue
Company (in millions) Beds
Omnicare $2,159 662,000
PharMerica $1,350 300,000
Genesis/NeighborCare $1,100 255,000
NCS HealthCare $626 209,000
Kindred Pharmacy Services $230 56,400
TABLE 1
Institutional Pharmacy Industry
and
 2001 Revenues
Source: Company annual reports.
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Medicaid eligibility; consequently, the Medicaid program bears most of
the financial responsibility for long-term care in the United States. Data
from the AHRQ show that, in 1996, nursing homes received 44 percent
of their total revenue from Medicaid, 19 percent from Medicare, and 34
percent from private sources (30 percent from out-of-pocket payments
and 4 percent from long-term care insurance).15
The three payment sources in this market use markedly different fi-
nancing structures to reimburse for drugs: Medicaid pays a discounted
price for drugs on a per-drug basis, Medicare imposes financial risk on
nursing homes by including drugs in the prospective payment rate, and
residents paying out-of-pocket typically pay a nondiscounted price for
drugs on a per-drug basis. These three reimbursement arrangements
offer very different incentives to nursing home and pharmacy opera-
tors (discussed further in the “Cost Containment” section, below).
Medicaid
State Medicaid programs generally reimburse for nursing home care in
a disaggregated fashion: payment for pharmaceuticals is done separately
from payment for residents’ care at the nursing facility. Pharmaceuticals
are typically reimbursed on a per-drug basis, while nursing facility care
is reimbursed according to a standard daily rate. (The exception to this
rule is in New York, where some drug costs are lumped into the Medicaid
daily rate for nursing facility care, thus placing the providers at risk for a
portion of nursing home drug expenditure.) Reimbursement for drugs is
paid directly from the Medicaid program to the pharmacy or is passed
through to the pharmacy via the nursing home.
Medicaid programs typically reimburse institutional pharmacies accord-
ing to the same methodology used for retail pharmacies, that is, reim-
bursement for brand-name drugs is the sum of an “ingredient” cost (usu-
ally set by the state at a certain discount from the average wholesale price,
or AWP, a figure used by payers and manufacturers to benchmark the
costs of drugs)16 plus a standard dispensing fee. However, some states
offer slightly higher reimbursement to institutional pharmacies to ac-
count for special differences between institutional pharmacies and retail
pharmacies. There are two sources of such additional reimbursement to
institutional pharmacies: (a) extra payments to cover institutional phar-
macies’ costs in procuring manufacturers’ unit dose products,17 and (b)
specially designated “long-term care (LTC) add-on” reimbursement (cur-
rently found in 11 states) intended to compensate institutional pharma-
cies for extra services they provide that retail pharmacies do not.18
Because DHHS’ Centers for Medicare and Medicaid Services (CMS) does
not systematically analyze nursing home drug spending separately from
overall Medicaid drug spending, there are no consistent national data on
Medicaid expenditures attributable to drug spending in the long-term care
setting.19 Investigation on a state-by-state basis, however, demonstrates
In 1996, nursing homes
received 44% of their
total revenue from
Medicaid, 19% from
Medicare, and 34%
from private sources.
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that spending varies as a function of the Medicaid program demograph-
ics in any given state. In Georgia, for example, where only 2 percent of
Medicaid recipients reside in nursing homes, the Medicaid program ex-
pends 14 percent of its total drug budget on long-term care pharmacy.20
In contrast, in Indiana, where 7 percent of Medicaid recipients live in
nursing homes,21 25 percent of total Medicaid pharmacy claims go to-
ward prescription drugs in nursing homes.22 These statistics lend sup-
port to the notion that nursing home residents consume a dispropor-
tionate share of Medicaid drug expenditures compared with their coun-
terparts in the community setting.
Medicare
In direct contrast to Medicaid, the Medicare program pays for nursing
home pharmaceuticals and nursing home facility care in one aggregated
bundle. For elderly and disabled beneficiaries, Medicare covers all or some
portion of the first 100 days of skilled nursing facility (SNF) care follow-
ing a three-day hospital stay,23 paying SNFs a per diem prospective rate
set by CMS. Like the Medicare inpatient hospital payment, the SNF pro-
spective rate covers almost all medically necessary drug use that occurs
during a resident’s stay.24 This means that Medicare does not pay for any
costs that exceed the previously determined rate and that SNFs are at risk
for the costs of all resident drug use during a Medicare-covered stay.
In their negotiations with institutional pharmacies, nursing homes some-
times contract to pay a capitated amount for Medicare-covered drugs,
thereby passing the risk of high drug use on to the pharmacy. However,
pharmacies often secure fee-for-service exclusions to these capitated ar-
rangements for some of the most expensive drugs. Institutional pharma-
cies are able to offer competitive drug prices to nursing homes because of
manufacturer discounts they receive when they include certain drugs on
their formulary; therefore, the pharmacies benefit when the prescribing
physicians adhere to the pharmacies’ formularies as closely as possible.
The American Society of Consultant Pharmacists has criticized the Medi-
care SNF prospective payment system for inadequately reimbursing nurs-
ing homes for resident drug use.25 In its May 2001 proposed rule update
to SNF payments, CMS acknowledged that it is difficult to account for
pharmacy costs in case-mix systems because drug costs do not necessar-
ily follow physical condition, resource use, or functional and clinical path-
ways.26 CMS announced that it would address this problem and others
by reexamining the SNF payment system. The proposed rule also includes
a provision to update the base year for the SNF market basket index,
which has the effect of giving drugs a higher weight within the index.27
Out-of-Pocket Payment
Residents paying out-of-pocket for nursing home care or assisted living
are typically billed separately by the pharmacy for their prescription
Nursing home residents
consume a dispropor-
tionate share of Medic-
aid drug expenditures.
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drugs. To maintain quality and administration control, nursing homes
and assisted living facilities strongly encourage or require residents to
use the pharmacy with which the facility has a contract.
Nursing home advocates believe that residents pay a higher price for
drugs dispensed by an institutional pharmacy than they would if they
received the same drug from a retail pharmacy.28 A recent media report
described how one institutional pharmacy’s charges for providing an
assisted living resident’s drugs were $6,702 a year higher than they
would have been under a mail order plan.29 In general, the institutional
pharmacy and nursing facility industries justify their higher prices for
drugs by citing the cost of additional specialized services provided to
residents in an institutional setting.
POLICY ISSUES
Cost Containment
Concern over the rise in spending on prescription drugs has prompted a
reexamination of opportunities for cost containment in all corners of the
health care system. With respect to prescription drugs in nursing homes,
state Medicaid programs have begun to emerge as laboratories for inno-
vation and experimentation.
Ingredient Cost Reimbursement — Ingredient cost (the cost of the drug
itself, considered separately from any dispensing fee paid to the phar-
macist) is typically the largest component of the total reimbursement
for any drug. Therefore, most state Medicaid cost containment efforts
have included some element of ingredient cost reimbursement adjust-
ment. In general, Medicaid programs have attempted to lower their in-
gredient cost reimbursements while attempting to guarantee pharma-
cies a reasonable profit.
Much of the research in this area has focused on trying to determine the
pharmacies’ actual drug acquisition costs, with the objective of using those
figures to determine the level at which Medicaid reimbursement should
be set. A recent DHHS Office of the Inspector General (OIG) study found
that “nontraditional” pharmacies (including nursing home, hospital, and
home infusion therapy pharmacies) acquired drugs at nearly a third be-
low AWP for brand name drugs.30 Since states typically reimburse phar-
macies at much higher rates, the OIG report implies that a substantial
portion of discounts received by pharmacies are not passed on to the
state and are instead kept by the pharmacies. The OIG report has met
with heavy criticism, however, especially from the pharmacy industry,
which has raised concerns about how the OIG’s figures were calculated.
For example, a University of Texas study performed on behalf of the
National Community Pharmacists Association and the National Associa-
tion of Chain Drug Stores argues that the OIG extrapolated its national
estimates from an unrepresentative sample of pharmacies and invoices.31
Research in the reim-
bursement area has
focused on trying to
determine the phar-
macies’ actual drug ac-
quisition costs.
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In response to this and other criticism, the OIG recently released addi-
tional analyses that broke out pharmacy acquisition costs by drug source
category.32
At present, over a dozen states (including Arkansas, Colorado, Connecti-
cut, Indiana, Kansas, Kentucky, Maryland, Massachusetts, Minnesota,
Mississippi, North Carolina, Oregon, Virginia, Washington, and West Vir-
ginia) are considering or have recently considered proposals to lower
their ingredient cost reimbursements for Medicaid pharmaceuticals. The
proposed reimbursement rates, which vary from AWP minus 11 percent
to AWP minus 30 percent, have met with varying levels of support.33 All
of the current proposals would apply equally in both the outpatient and
nursing home settings; there appear to be no current proposals that would
single out institutional pharmacies for greater or lesser reductions.
Dispensing Fees — Current legislative proposals vary with regard to
their approaches to pharmacy dispensing fees. Some states (for example,
Mississippi) are attempting to lower both ingredient reimbursements and
dispensing fees, while other states (for example, Minnesota) would re-
duce ingredient reimbursement while increasing dispensing fees. A bud-
get proposal from Kentucky would decrease dispensing fees for retail
pharmacies but leave them unchanged for institutional pharmacies.34
Special Reimbursements for Institutional Pharmacies — The current
policy environment is marked by a growing awareness of the special
requirements (and costs) associated with dispensing pharmaceuticals in
the nursing home setting. As mentioned above, some states recognize
the unique circumstances of institutional pharmacies by offering them
slightly higher reimbursements than they offer retail pharmacies. The
first way this is done is by compensating institutional pharmacies for
the additional cost associated with procuring manufacturers’ unit dose
products. Some states offer an even higher reimbursement when phar-
macies buy manufacturers’ products in bulk and then repackage the drugs
themselves as unit doses. While all states allow pharmacies to reuse
original manufacturer-packed unit dose products if certain conditions
are met, recent legislation in several states has also allowed pharmacies
to reuse pharmacy-repacked unit dose drugs under certain circumstances,
thus lowering their costs.35
The second way in which states can offer higher reimbursement to insti-
tutional pharmacies is through designated “LTC add-on” reimbursement.
Eleven states presently have arrangements to reimburse institutional phar-
macies an additional amount ranging from $0.30 to $1.40 per prescrip-
tion, above and beyond the ingredient cost and dispensing fee, as com-
pensation for extra services performed in the institutional setting.36
A number of key questions underlie the current debate over institutional
pharmacy reimbursement. How costly are the added services provided
by institutional pharmacies? Are there offsetting savings that nursing
homes can achieve? Should any net costs be added to Medicaid payment
Some states offer insti-
tutional pharmacies
slightly higher reim-
bursements than they
offer retail pharmacies.
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rates? Two recent studies have attempted to shed light on these ques-
tions. A December 2000 study of institutional pharmacy dispensing costs
released by the Pennsylvania General Assembly37 found that long-term
care pharmacies incur additional costs of $2.87 per prescription for the
above services; the report recommended that Pennsylvania Medicaid
consider an LTC add-on for institutional pharmacies above its standard
reimbursement (AWP minus 10 percent plus a dispensing fee of $4.00
per prescription). A second study released by the Long-Term Care Phar-
macy Alliance in April 2002 reported that institutional pharmacies face
dispensing costs of $4.32 per prescription higher than traditional retail
pharmacies.38 It should be emphasized that both of these studies con-
fined themselves to an analysis of dispensing costs and did not examine
drug acquisition costs; therefore, the discounts on drugs and high mar-
gins for institutional pharmacies (as reported by the OIG) were not taken
into consideration.
Alternative Risk Sharing Arrangements — As noted above, New York
Medicaid has a unique arrangement for financing nursing home drug spend-
ing. By including the costs for many drugs into the prospective daily rate
for nursing facility care, New York effectively places nursing homes at fi-
nancial risk for a portion of nursing home drug spending, as takes place
under Medicare. Several high-priced drugs are excluded from this arrange-
ment and are reimbursed by the traditional per-drug methodology.
The economic incentives engendered by New York Medicaid and by
Medicare are at odds with those produced by traditional Medicaid reim-
bursement. Under capitation, nursing homes may benefit when fewer
drugs are prescribed, since fewer dollars are diverted to the pharmacy to
pay for drugs. With the latter approach, nursing homes have no economic
incentive to control drug utilization, and in fact pharmacies benefit when
more drugs are prescribed. These different incentive systems raise im-
portant issues for nursing home care. On one hand, placing the nursing
home at risk for drug spending might curtail overall pharmaceutical costs
and may in fact encourage quality improvement programs aimed at re-
ducing inappropriate medication use. On the other hand, risk sharing
may encourage providers to limit access to medications and to deny care
to sicker (and thus more expensive) beneficiaries.
Other Initiatives — Most states have been experimenting with a variety
of approaches other than reimbursement cuts as avenues through which
to control Medicaid drug spending. Programs such as preferred drug
lists, limits on brand-name drugs, and therapeutic substitution are all
currently used to varying degrees in many states. However, program
policies differ by state with respect to their impact on nursing home popu-
lations. Legislation in Florida, for example, exempted nursing homes from
a newly adopted preferred drug list but expanded the state’s four-brand
limit to Medicaid-covered nursing home residents. This policy requires
that a Medicaid beneficiary must receive prior authorization from the
state to receive a fifth or higher brand-name medication in any given
New York places nurs-
ing homes at financial
risk for a portion of
nursing home drug
spending.
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month. Michigan, on the other hand, included nursing homes in its cur-
rent preferred drug list and prior authorization program.39
To date, five states have obtained approval from the Bush administra-
tion to implement Pharmacy Plus waivers, which allow prescription drug
coverage for seniors who would not otherwise qualify for Medicaid.
While the Pharmacy Plus program is targeted at low-income seniors
who receive prescription drugs in an outpatient setting, it is conceivable
that states could use Pharmacy Plus to provide drug-only coverage to
nursing home residents that have not yet “spent down” to full Medicaid
coverage. However, eligibility for Pharmacy Plus may be short-lived as
residents continue to spend down into full Medicaid eligibility, and
spending limits in some states could further limit the program’s applica-
bility in this context.
Quality Improvement
Nursing home quality of care emerged as a visible patient advocacy
issue in the mid 1970s and early 1980s. Public concern over poor nursing
home quality culminated in a landmark Institute of Medicine report in
1986 that highlighted widespread quality problems and recommended
stronger federal regulations.40 In response, Congress passed the Nurs-
ing Home Reform Act as part of the Omnibus Budget Reconciliation Act
(OBRA) of 1987.41 By strengthening quality standards, upgrading the
survey process, and stipulating quality requirements that must be met
for nursing homes to participate in the Medicare and Medicaid pro-
grams, OBRA 1987 set the stage for subsequent quality improvement
efforts, some of which are well established and some of which continue
to evolve. The most significant quality assurance initiatives related to
drug therapy include limits on chemical restraints, limits on other un-
necessary or harmful drug use, efforts to discourage polypharmacy (the
practice of prescribing too many medicines to a patient), mandated drug
regimen reviews by consultant pharmacists, and initiatives to dissemi-
nate geriatric best practice information to physicians.
Limits on Chemical Restraints — A major quality improvement goal of
the patient advocacy movement has been to limit use of chemical re-
straints in nursing facilities. Because of concerns that nursing homes
were using drugs to sedate residents inappropriately, OBRA 1987 man-
dated that nursing home residents be free from “physical or chemical
restraints imposed for the purposes of discipline or convenience and
not required to treat a resident’s medical symptoms.”42 A nursing home
may impose restraints only to ensure resident safety and only under a
physician’s written order. These orders must specify the duration and
circumstances under which the restraints may be used.
DHHS regulations further limit chemical restraints by requiring nursing
homes to ensure that residents “who have not used antipsychotic drugs
are not given these drugs unless antipsychotic drug therapy is neces-
sary to treat a specific condition as diagnosed and documented in the
Patient advocates have
sought to limit the use
of chemical restraints in
nursing facilities.
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clinical record.” For residents who use antipsychotic drugs, nursing homes
must make an effort to discontinue these drugs by making gradual dose
reductions and by conducting behavioral interventions.43
There is evidence that these laws and regulations have been effective in
preventing inappropriate use of chemical sedation. In November 2001,
the OIG found that 85 percent of nursing home residents’ psychotropic
drug use was medically appropriate and 8 percent was inappropriate (the
remainder was unclear).44 Despite these positive findings, advocates re-
main concerned that, faced with increasing difficulties in hiring and re-
taining staff, nursing homes may use chemical restraints inappropriately
as a substitute for maintaining adequate staffing levels.45 The OIG report
does not specifically address the relationship of psychotropic drug use to
staffing levels, but at least one facility in the study with low psychotropic
drug use had high staffing levels, while at least one facility with high
drug use had low staffing levels.46
Limits on Unnecessary and Harmful Drug Use — Limits on chemical
restraints led naturally into broader regulation of unnecessary and harm-
ful drug use. DHHS now mandates that each nursing home resident’s
drug regimen be free from unnecessary drugs, with an unnecessary drug
defined as “any drug used in excessive dose, for excessive duration, with-
out adequate monitoring or without adequate indications for its use, or
in the presence of adverse consequences.”47 In order to ensure appropri-
ate drug dispensing and monitoring, OBRA 1987 requires “pharmaceuti-
cal services (including procedures that assure the accurate acquiring, re-
ceiving, dispensing, and administering of all drugs and biologicals) to
meet the needs of each resident.”48
Over the last ten years, efforts to limit unnecessary and harmful drug
use have incorporated the results of emerging clinical research on drug
metabolism, side effects, and interactions in geriatric patients. For example,
since 1991 a group of clinicians led by Mark Beers, M.D., editor of the
Merck Manual, has produced a list of drugs to be avoided in elderly pa-
tients along with a list of recommended alternatives. DHHS incorporated
many of the “Beers’ list” recommendations into the drug therapy guide-
lines issued in its 1999 Survey Procedures and Interpretive Guidelines.
The Beers’ list recommendations are also included in CMS surveys on
unnecessary drug use and in the monthly drug regimen reviews described
below. Recent research suggests significant room for improvement in this
area—some 50 percent of nursing home residents in a recent AHRQ-
funded study were found to have at least one potentially inappropriate
medication prescription, defined according to Beers’ criteria.49
Efforts to Discourage Polypharmacy — Polypharmacy is frequently cited
as a serious quality issue facing nursing home residents. Clinical studies
have shown that the number of drugs prescribed is correlated with ad-
verse drug events (preventable or nonpreventable events related to the
use of medications).50 A person taking seven medications is about 14 times
more likely to have an adverse drug event than a person taking one.51
Polypharmacy is fre-
quently cited as a seri-
ous quality issue facing
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CMS monitors polypharmacy through the collection of nursing home
resident data via its Long-Term Care Minimum Data Set (MDS).52 Using
MDS data, the University of Wisconsin’s Center for Health Systems Re-
search and Analysis has developed quality indicators for state survey-
ors and CMS. In the most recent set of CMS quality indicators, residents
who are on more than nine different drugs are flagged for further inves-
tigation. Some groups, such as the American Society of Consultant Phar-
macists, have characterized the nine-medication flag as arbitrary, stat-
ing that it could “compromise residents’ ability to receive needed and
appropriate medications.”53
Drug Regimen Reviews by Consultant Pharmacists — To provide a
vehicle for monitoring drug safety and facilitating compliance with regu-
latory requirements, OBRA 1987 included a provision requiring monthly
(or more frequent) drug regimen reviews by consultant pharmacists.54
DHHS regulations have since elaborated on the consultant pharmacist
requirement, stipulating that nursing homes “employ or obtain the ser-
vices of a licensed pharmacist who: (1) provides consultation on all as-
pects of the provision of pharmacy services in the facility; (2) establishes
a system of records of receipt and disposition of all controlled drugs in
sufficient detail to enable an accurate reconciliation; and (3) determines
that drug records are in order and that an account of all controlled drugs
is maintained and periodically reconciled.” The regulations also require
the review of each resident’s drug regimen at least once a month by a
licensed pharmacist; the pharmacist “must report any irregularities to
the attending physician and the director of nursing, and these reports
must be acted upon.”55
The primary focus of the consultant pharmacist’s drug regimen review
is to ensure that residents are receiving medications appropriate to their
medical diagnoses, their age, and their functional status. Since a number
of physicians may be prescribing for any one nursing home resident, con-
sultant pharmacists ensure that the drugs do not have any interactions
with each other. Consultant pharmacists make recommendations about
resident drug use to the nursing facilities and to residents’ physicians.56
Physicians, however, bear ultimate responsibility for the resident and must
decide whether to take the consultant pharmacist’s advice.
As mentioned above, New Jersey prohibits nursing homes from using
consultant pharmacists affiliated with the nursing home’s institutional
pharmacy. The requirement for independent consultant pharmacists ad-
dresses the potential conflict of interest that exists when consultant phar-
macists make recommendations regarding residents’ drug regimens.
Disseminating Best Practice Information to Physicians — The last few
years have produced a growing body of research regarding the special
needs and characteristics of geriatric patients with respect to drug use.
An emerging consensus in the clinical literature suggests that, as a result
of the natural aging process, elderly patients undergo physiologic changes
New Jersey prohibits
nursing homes from
using consultant phar-
macists affiliated with
the nursing home’s in-
stitutional pharmacy.
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that affect drug metabolism, side effects, and interactions. The implica-
tion for nursing home residents is that physicians need to be familiar with
the differences between elderly patients and their younger counterparts
and to adjust their prescribing patterns accordingly.
However, prescribing physicians are not always equipped with the most
up-to-date information regarding drug effects in geriatric patients, for
several reasons.57 First, physicians in the nursing home setting may come
from several different training backgrounds (for example, internal medi-
cine, psychiatry, dermatology) and may lack specialty training in geriat-
ric medicine.58 Second, physicians may be either too busy or too inun-
dated by a steady barrage of new information to distill and incorporate
new recommendations affecting elderly patients. Third, good research
data on elderly patients is still hard to find for even the most common
clinical situations—a 2001 report in the Journal of the American Medical
Association found that while people over 75 accounted for 37 percent of
myocardial infarction (heart attack) hospitalizations in 1995, only 13 per-
cent of the total population of all clinical trials for acute coronary syn-
dromes fell within this age group.59 Finally, physicians may just not know
where to look for information; a physician recently interviewed by the
Wall Street Journal reported that “information about dosing and how cer-
tain drugs affect the elderly can be impossible to come by.”60
Some states are trying to address this problem by conducting outreach
initiatives to communicate best practice information to physicians of
nursing home residents. In Arkansas, for example, a decision support
system tied into the Medicaid claims system identifies physicians whose
prescribing patterns deviate from standard guidelines and flags them
as candidates for educational programs.61 The program has achieved
limited success, however, due primarily to its voluntary nature and lack
of physician interest.62
Other Efforts — A number of new quality improvement initiatives have
been gaining momentum in tandem with growing public concern over
medical error prevention and with growing awareness of the capabilities
of health care information technology. Pharmacy automation, for example,
can both increase operating efficiencies and improve quality of care by
reducing dispensing errors and ensuring that physician orders are accu-
rate.63 Additionally, robotic packaging in patient-specific unit-dose enve-
lopes can help reduce labor demands while ensuring that residents are
receiving the appropriate medications.
CONCLUSION
As policymakers begin to consider a variety of issues surrounding drug
therapy, the management of drug costs in the long-term care setting
deserves special attention. It is critical to consider the unique elements
of the nursing home environment, the alternative arrangements for fi-
nancing nursing home drug expenditures, the nuanced debate over long-
15
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term care pharmaceutical reimbursement, and evolving initiatives re-
lated to quality of care.
As often happens, state policy in this area is changing more rapidly than
federal policy, and differences among states provide an opportunity for
the identification of best practices. Federal policymakers may find it use-
ful to closely monitor state activities and assess which innovations in pay-
ment, quality, and operations may be appropriate for national applica-
tion to the Medicaid and Medicare programs.
Unfortunately, there is a dearth of data on which to base policy evalua-
tions in this area. Despite the fact that the federal government pays more
than half of Medicaid costs, CMS has not systematically analyzed data on
which drugs are used by nursing home residents and how much is paid
for them. Moreover, not all states have data available that are public or
accessible. In the absence of a federal reporting requirement, evaluations
of nursing home drug spending on a state-by-state basis will be a critical
tool for illuminating the details of this important policy area. More states
will likely become interested in such evaluations as they continue in their
efforts to control Medicaid pharmaceutical spending.
Finally, nursing home residents stand to benefit from further research on
quality, especially with regard to the effects of prescription drugs on geri-
atric patients. As pharmaceutical therapies continue to emerge rapidly,
public programs could serve an important function in collecting, evalu-
ating, and disseminating information to providers. Establishing continu-
ous quality improvement processes in nursing homes would also help to
ensure that residents reap the benefits of practice guidelines and other
quality improvement initiatives.
ENDNOTES
1 U.S. Census Bureau, “Aging in the Americas into the XXI Century,” wallchart, U.S.
Department of Commerce; available November 6, 2002, at http://www.census.gov/ipc/
www/agingam.html.
2 Celia S. Gabrel, “An Overview of Nursing Home Facilities: Data from the 1997 Na-
tional Nursing Home Survey,” National Center for Health Statistics, Centers for Disease
Control and Prevention, Advance Data, 311 (March 1, 2000); available November 6, 2002, at
http://www.cdc.gov/nchs/data/ad/ad311.pdf.
3 National Center for Health Statistics, “National Nursing Home Survey,” Centers for
Disease Control and Prevention; accessed April 12, 2002, at http://www.cdc.gov/nchs/
about/major/nnhsd/nnhsd.htm.
4 Jeffrey Rhoades and John Sommers, “Expenses and Sources of Payment for Nursing
Home Residents, 1996,” Medical Expenditure Panel Survey Research Findings no. 13 (AHRQ
Pub. No. 01-0010), Agency for Healthcare Research and Quality, Rockville, Md., 2000, 7.
5 Dianne E. Tobias and Mark Sey, “General and Psychotherapeutic Medication Use in 328
Nursing Facilities: A Year 2000 National Survey,”Consultant Pharmacist, 16, no. 1 (2001): 52.
6 Jerry Avorn and Jerry H. Gurwitz, “Drug Use in the Nursing Home,” Annals of Internal
Medicine, 123 (1995): 195-204.
16
NHPF Issue Brief No.784 / November 12, 2002
7 Preliminary data from Office of Disability, Aging, and Long-Term Care, “Profiles of
Medication Use by Institutionalized Medicare Beneficiaries in Nursing Homes and As-
sisted Living Facilities” (HHS-100-01-002), Assistant Secretary for Planning and Evalua-
tion, Department of Health and Human Services, March 2002 (draft report: analysis com-
plete, text in development).
8 Dianne E. Tobias and Charles C. Pulliam, “General and Psychotherapeutic Medication
Use in 878 Nursing Facilities: A 1997 National Survey,” Consultant Pharmacist, 12, no. 12
(1997): 1401-8.
9 Tobias and Sey, “General and Psychotherapeutic Medication,” 65–69.
10 Pharmaceutical Research and Manufacturers of America, “New Drugs in Develop-
ment Increase to 785 for Diseases Affecting Older Americans,” 2001 Survey, New Medicines
in Development for Older Americans, PhRMA, Washington, D.C., 2001, 1; available Novem-
ber 12, 2002, at http://www.phrma.org/newmedicines/resources/
older_americans_2001.pdf.
11 Long Term Care Pharmacy Alliance, “Members”; accessed October 16, 2002, at http://
www.ltcpa.org/public/memberinfo/default.asp.
12 NCS HealthCare, Inc., “NCS HealthCare Advises Stockholders to Take No Action at
This Time in Response to Omnicare’s Tender Offer,” press release, August 9, 2002; accessed
October 16, 2002, at http://www.ncshealth.com/sll.htm.
13 Hank Kozek, New Jersey Department of Health and Senior Services, telephone inter-
view, November 1, 2002.
14 Gary Erwin, Omnicare, Inc., telephone interview, December 11, 2001; Leigh Davitian,
American Society of Consultant Pharmacists, telephone interview, November 15, 2001.
15 Rhoades and Sommers,“Expenses and Sources of Payment.”
16 For further information on average wholesale price, see Dawn M. Gencarelli, “Average
Wholesale Price for Prescription Drugs: Is There a More Appropriate Pricing Mechanism?”
NHPF Issue Brief No. 75, June 7, 2002.
17 Legislative Budget and Finance Committee, “A Study of Long-Term Care Pharmacy
Dispensing Costs,” Pennsylvania General Assembly, December 2000; available November
12, 2002 at http://www.ltcpa.org/public/issues/papers/study_costs.asp.
18 American Society of Consultant Pharmacists (ASCP), “ASCP Analysis of Medicaid
Pharmacy Changes,” February 22, 2002; available November 6, 2002, at http://
www.ascp.com/public/ga/2002/docs/State2_25.pdf.
19 Jim Verdier, Senior Fellow, Mathematica Policy Research, Inc., telephone interview,
October 15, 2001.
20 Data from Georgia Department of Community Health (DCH).
21 Jim Verdier, Mathematica Policy Research, Inc., telephone interview, October 15, 2001.
22 Jim Verdier, Mathematica Policy Research, Inc., telephone interview, October 15, 2001.
23 Committee on Ways and Means, 2000 Green Book, U.S. House of Representatives, 106th
Congress, Washington, D.C., October 6, 2000, 126.
24 Ways and Means, 2000 Green Book, 126-127.
25 American Society of Consultant Pharmacists, “SNF PPS Proposed Rule Updating Pay-
ments for FY 2002”; accessed February 15, 2002, at http://ascp.com/public/ga/2001/
pps02update.shtml.
26 Federal Register, 66, no. 91, Thursday, May 10, 2001, 23991.
27 Federal Register, 23990.
28 Sara Burger, National Citizens’ Coalition for Nursing Home Reform, telephone interview,
November 16, 2001.
17
NHPF Issue Brief No.784 / November 12, 2002
29 Melody Simmons, “Blistering Drug Costs at Assisted Living Facilities,” Washington Post,
November 27, 2001.
30 Office of the Inspector General, “Medicaid Pharmacy—Actual Acquisition Cost of Brand
Name Prescription Drug Products” (A-06-00-00023) U.S. Department of Health and Hu-
man Services, Washington, D.C., August 2001, 4; available November 6, 2002, at http://
oig.hhs.gov/oas/reports/region6/60000023.pdf.
31 Michael Johnsrud, Marv Shepherd, and Kenneth Lawson, “A Review of the HHS Office of
Inspector General Report: ‘Medicaid Pharmacy—Actual Acquisition Cost of Brand Name
Prescription Drug Products,’” Center for Pharmacoeconomic Studies, University of Texas,
Austin, December 2001.
32 Office of Inspector General, “Medicaid Pharmacy—Additional Analyses of the Actual
Acquisition Cost of Prescription Drug Products” (A-06-02-00041), U.S. Department of
Health and Human Services, Washington, D.C., September 2002.
33 ASCP, “Medicaid Pharmacy Changes.”
34 ASCP, “Medicaid Pharmacy Changes.”
35 Legislative Budget and Finance, “Long-Term Care Pharmacy.”
36 ASCP, “Medicaid Pharmacy Changes.”
37 Legislative Budget and Finance, “Long-Term Care Pharmacy.”
38 Long-Term Care Pharmacy Alliance and BDO Seidman, LLP, “The LTCPA Institutional
Pharmacy Dispensing Cost Study,” April 2002; accessed October 16, 2002, at http://
www.ltcpa.org/public/issues/papers/bdo_execsummary.asp.
39 Cathy Bernasek, Cathy Harrington, Rajeev Ramchand, and Dan Mendelson (Health Strat-
egies Consultancy), Florida’s Medicaid Prescription Drug Benefit: A Case Study, Kaiser Commis-
sion on Medicaid and the Uninsured, Washington, D.C., February 2002, 10.
40 Institute of Medicine, Improving the Quality of Care in Nursing Homes (Washington, D.C.:
National Academy Press, 1986.).
41 Social Security Act, Title 19, Sec. 1919.
42 Social Security Act, Title 19, Sec. 1919 (c) (1) (A) (ii).
43 42 C.F.R. 483.25 (l) (2) (ii).
44 Office of the Inspector General, “Psychotropic Drug Use in Nursing Homes” (OEI-02-00-
00490), U.S. Department of Health and Human Services, Washington, D.C., November 2001, 8.
45 Burger, telephone interview.
46 Burger, telephone interview.
47 42 C.F.R. 483.25 (l) (1).
48 Social Security Act, Title 19, Sec. 1919 (b) (4) (A) (iii).
49 Denys Tsz-Wai Lau, “Potentially Inappropriate Medication Prescriptions among Geriat-
ric Nursing Home Residents: Preliminary Findings on Its Scope and Associated Resident and
Facility Characteristics,” presentation, 129th Meeting of the American Public Health Asso-
ciation, Atlanta, Georgia, October 23, 2001.
50 Jerry H. Gurwitz et al., “Incidence and Preventability of Adverse Drug Events in Nursing
Homes,” American Journal of Medicine, 109, no.2 (2000), 87-94; Jerry Avorn and Jerry H.
Gurwitz, “Drug Use in Nursing Homes,” Annals of Internal Medicine, 123, no. 3 (1995), 195-
204; Chunliu Zhan et al., “Potentially Inappropriate Medication Use in the Community
Dwelling Elderly,” JAMA, 286, no. 22 (2001), 2823-2829; Terry Field et al., “Risk Factors for
Adverse Drug Events among Nursing Home Residents,” Archives of Internal Medicine, 161, no.
13 (2001), 1630.
51 Michael Orey, “Do No Harm: Doctor Creates a Rift with a Radical Notion: Prescribe
Fewer Pills,” Wall Street Journal, June 22, 2001.
18
NHPF Issue Brief No.784 / November 12, 2002
52 Center for Health Systems Research and Analysis, “Quality Indicators: Nursing Homes”;
accessed March 5, 2001 at http://www.chsra.wisc.edu/CHSRA/Quality_Indicators/
Nursing_Homes/domaindesc.htm.
53 American Society of Consultant Pharmacists, “ASCP Comments on HCFA ‘Quality
Indicators’ – Revised,” September 14, 1999; accessed February 20, 2001 at http://
www.ascp.com/public/news/pre-2000/hcfaqualindrev.shtml.
54 Social Security Act, Title 19, Sec. 1919 (b) (4) (iii); 42 C.F.R. 483.60.
55 42 C.F.R. 483.60.
56 Davitian, telephone interview.
57 Orey, “Do No Harm”; Manju Beier, Geriatric Consultant Resources, telephone inter-
view, December 11, 2001.
58 Orey, “Do No Harm”; Beier, telephone interview.
59 Patrick Y. Lee et al., “Representation of Elderly Persons and Women in Published Ran-
domized Trials of Acute Coronary Syndromes,” JAMA, 286, no. 6, (2001), 710.
60 Orey, “Do No Harm.”
61 Arkansas Medicaid, “Message from the Director”; accessed July 7, 2002, at
www.medicaid.state.ar.us/.
62 Ray Hanley, Arkansas Medicaid, telephone interview, October 25, 2001.
63 Armon B. Neel Jr., “Long-Term Care Pharmacy Automation: An Idea Whose Time Has
Come,” Consultant Pharmacist, 16, no. 9 (2001), 47.
